The technology platform won the award for its work using AI to improve precision medicine.
OncoHost is officially an AI award winning company.
The technology company announced that it has been named the winner of the Business Intelligence Group’s Artificial Intelligence Awards program. According to a press release,1 OncoHost earned the title due to its work using AI to improve the develop of precision medicine treatments.
OncoHost’s PROphet platform cinched the win for the company. Developed to help fight back against resistance to cancer treatment, the platform is able to analyze and predict proteomic profiles in blood plasma. Using this information, it’s able to build computational models that can be used to predict a patient’s odds of benefiting from certain treatments.
In the press release, OncoHost’s CEO Ofer Sharon, MD, said, “We are honored to receive the AI Excellence Award, which recognizes our commitment to advancing precision medicine through innovative machine learning applications. Our PROphet® platform is the result of rigorous development and validation on real-world patient data, setting it apart from retrospective analyses. This distinction ensures that our platform provides clinicians with reliable, actionable insights to personalize cancer treatment. Our ongoing clinical trial underscores our dedication to evidence-based medicine, and we are excited about the potential of PROphet® to transform care for cancer patients worldwide."
In the same press release, Business Intelligence Group’s chief nominiations officer also said, “We are truly honored to recognize OncoHost with this prestigious award. The unwavering commitment of their team to excellence and their innovative AI applications have catapulted them to this remarkable achievement. Congratulations to the entire organization!"
This story is just the latest example of AI-based technology being incorporated into the pharmaceutical industry. The technology has been around for several years, but it has become a mainstream sensation over the past year-and-a-half. Most of the headlines around AI have centered around generative AI, which is popular among general audiences for able to create words, images, or even videos based on simple prompts.
While generative AI has been incorporated by elements of the pharma industry, most companies are focusing on figuring out ways to use data sorting algorithms and AI. These programs, such as the one used by OncoHost, have shown themselves to be highly beneficial, especially in the drug development phase.
Researchers are able to use them to gather large amounts of information from a variety of sources and start analyzing the data at a much faster pace than previous efforts. Based on the number of companies that are starting to see the benefits of incorporating AI, the Business Intelligence Group’s award will likely have even more competition next year.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.